Pancreatic Enzymes (Pancrelipase) per Bloating and Intestinal Gas

A Evidenze Più grandi trial clinici mostrano in modo costante benefici significativi.

Standard of care for exocrine pancreatic insufficiency. Pancreatic enzyme replacement therapy (25,000-40,000 lipase units/meal) normalizes fat absorption and helps resolve steatorrhea. FDA-approved medications (Creon, Zenpep).

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dpancreatic\u002Denzymes\u0026condition\u003Dbloating\u002Dand\u002Dgas'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

In sintesi

Key Study Findings

Randomized Controlled Trial 26 weeks Open-label

Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control …

Dose: None vs: Usual nutrition care Outcome: Quality of life (EORTC-QLQ C30 summary score) Effetto: None None

Popolazione: Adults with pancreatic cancer (borderline/locally advanced/metastatic)

Case Reports n=1 Open-label

Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review.

Dose: 20 mg once daily vs: None Outcome: Drug-induced pancreatitis Effetto: None None

Popolazione: 28-year-old woman with severe depression

Review

Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer.

Dose: Pancreatic enzyme replacement therapy (PERT) vs: None Outcome: EPI symptom management in pancreatic cancer Effetto: None None

Popolazione: Patients with pancreatic cancer and EPI

Case Reports

An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis.

Dose: None vs: None Outcome: pain reduction Effetto: None None

Popolazione: None

Review

AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert …

Dose: PERT (pancreatic enzyme replacement) vs: None Outcome: EPI diagnosis and treatment guidelines Effetto: None None

Popolazione: Patients with exocrine pancreatic insufficiency

Other n=35 26.0 weeks

Isolated Amylase Deficiency in Children and Its Clinical Implication.

Dose: None vs: None Outcome: Diarrhea outcomes Effetto: None None

Popolazione: children

Key Statistics

Studi

800

Partecipanti

↑

Positive

Grado

Referenced Papers

Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, … Other

Nutrition journal 2025

Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review. Case Report

Frontiers in medicine 2025

Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer. Review

Pharmacy (Basel, Switzerland) 2024 2 citazioni

AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Review

Gastroenterology 2023 87 citazioni

An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis. Case Report

Cureus 2023 1 citazioni

Isolated Amylase Deficiency in Children and Its Clinical Implication. Other

Journal of pediatric … 2019 14 citazioni

Long alimentary limb duodenal switch (LADS): a short-term prospective randomized trial. RCT

Surgery for obesity … 2018 10 citazioni

Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. Other

The American journal … 2018 9 citazioni

Diagnosis and management of pancreatic exocrine insufficiency. Other

The Medical journal … 2017 59 citazioni

Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome … Other

The patient 2017 55 citazioni

Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. Systematic Review

Digestive surgery 2017 37 citazioni

A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. Review

The American journal … 2017 25 citazioni

[Small intestine bacterial overgrowth in patients with chronic pancreatitis]. Other

Revista medica de … 2008

Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. RCT

Digestive diseases and … 1999 40 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:: 25,000-40,000 lipase units per meal
epiadults:: 25,000-50,000 lipase units with meals, 10,000-25,000 with snacks
epipediatric:: 500-2,500 lipase units/kg/meal (max 10,000 units/kg/day)

Limite massimo: 10,000 lipase units/kg/day (higher doses associated with fibrosing colonopathy)

Dosaggi studiati nella ricerca

Dosaggio	Durata	Effetto	N
None	26 weeks	Mixed	--
20 mg once daily	--	Negative	1
Pancreatic enzyme replacement therapy (PERT)	--	Positive	--
None	--	Mixed	--
PERT (pancreatic enzyme replacement)	--	Positive	--
None	26.0 weeks	Mixed	35
16 g	8.7 weeks	Mixed	--
None	52.0 weeks	Mixed	20

Momento migliore per l'assunzione: With meals and snacks; take half the dose at the beginning and half during the meal

Safety & Side Effects

Effetti collaterali segnalati

⚠ Abdominal pain and cramping
⚠ Nausea
⚠ Fibrosing colonopathy at very high doses (rare; primarily in cystic fibrosis patients)
⚠ Hyperuricemia (high doses of protease can increase uric acid)

Interazioni note

● Calcium carbonate and magnesium hydroxide antacids (may reduce enzyme activity)
● Acarbose and miglitol (pancreatic amylase may counteract alpha-glucosidase inhibitors)
● Iron supplements (protease may reduce iron absorption)
● Proton pump inhibitors (may improve enzyme efficacy by reducing acid denaturation)

Livello di assunzione massimo tollerabile: 10,000 lipase units/kg/day (higher doses associated with fibrosing colonopathy)

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Pancreatic Enzymes (Pancrelipase) help with Bloating and Intestinal Gas?

Based on 12 studies with 800 participants, there is strong evidence from multiple clinical trials that Pancreatic Enzymes (Pancrelipase) may support Bloating and Intestinal Gas management. Our evidence grade is A (Strong Evidence).

How much Pancreatic Enzymes (Pancrelipase) should I take for Bloating and Intestinal Gas?

Studies have used various dosages. A commonly studied range is 25,000-40,000 lipase units per meal. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Pancreatic Enzymes (Pancrelipase)?

Reported side effects may include Abdominal pain and cramping, Nausea, Fibrosing colonopathy at very high doses (rare; primarily in cystic fibrosis patients), Hyperuricemia (high doses of protease can increase uric acid). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Pancreatic Enzymes (Pancrelipase) and Bloating and Intestinal Gas?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 12 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Altri ingredienti per Bloating and Intestinal Gas

Ginger B Lactobacillus reuteri B Alpha-Galactosidase B Medium-Chain Triglycerides (MCT Oil) C

Verdetto rapido

Evidence Strength92%

High confidence

Analisi degli studi

RCT (2)Meta (0)Other (10)

Confronta le alternative

Scoprite come si confrontano altri ingredienti per questa condizione.

Visualizza tutti gli ingredienti per Bloating and Intestinal Gas

Approfondimenti

References

[1] Emma McShane et al.. Nutr J. 2025. Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, … doi:10.1186/s12937-025-01113-9 PubMed
[2] Yangpeng Wu et al.. Front Med (Lausanne). 2025. Case Report: A case of drug-induced pancreatitis caused by paroxetine with a literature review. doi:10.3389/fmed.2025.1688065 PubMed
[3] Mary Acelle G Garcia et al.. Pharmacy (Basel). 2024. Rational Prescribing of Pancreatic Enzymes for Patients with Pancreatic Cancer. doi:10.3390/pharmacy12020047 PubMed
[4] David C Whitcomb et al.. Gastroenterology. 2023. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. doi:10.1053/j.gastro.2023.07.007 PubMed
[5] Nabi Nadia et al.. Cureus. 2023. An Infected Intrahepatic Pancreatic Pseudocyst and Calcified Pancreas: A Rare Complication of Chronic Pancreatitis. doi:10.7759/cureus.35384 PubMed
[6] Puanani Hopson et al.. J Pediatr Gastroenterol Nutr. 2019. Isolated Amylase Deficiency in Children and Its Clinical Implication. doi:10.1097/MPG.0000000000002317 PubMed
[7] Anabelle Cloutier et al.. Surg Obes Relat Dis. 2018. Long alimentary limb duodenal switch (LADS): a short-term prospective randomized trial. doi:10.1016/j.soard.2017.08.028 PubMed
[8] Yalda Zolghadri et al.. Am J Pathol. 2018. Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. doi:10.1016/j.ajpath.2017.11.014 PubMed
[9] Mehrdad Nikfarjam et al.. Med J Aust. 2017. Diagnosis and management of pancreatic exocrine insufficiency. doi:10.5694/mja16.00851 PubMed
[10] Colin D Johnson et al.. Patient. 2017. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome … doi:10.1007/s40271-017-0233-0 PubMed
[11] Jennifer Straatman et al.. Dig Surg. 2017. Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. doi:10.1159/000454958 PubMed
[12] Samer Alkaade et al.. Am J Manag Care. 2017. A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. PubMed
[13] Carla Mancilla A et al.. Rev Med Chil. 2008. [Small intestine bacterial overgrowth in patients with chronic pancreatitis]. PubMed
[14] F Suarez et al.. Dig Dis Sci. 1999. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. doi:10.1023/a:1026675012864 PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.